Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
The provided label excerpts explicitly support the short-term duration limitation (up to two or three weeks) and acute, painful musculoskeletal discomfort indications. However, most other claims (e.g., side effects, driving/operating machinery, dependence/misuse phrasing, drug–drug interaction counseling, and comparisons to other muscle relaxants) are not supported or not verifiable from the supplied label text excerpts, so overall alignment is only partial.
Category Scores
Accurate Statements
Carisoprodol is used for short-term relief of painful muscle spasms associated with acute, painful musculoskeletal conditions.
Supported by SECTION 1 — INDICATIONS AND USAGE (acute, painful musculoskeletal conditions; limit to short periods).
Carisoprodol is typically used short-term (days to a few weeks).
Supported by SECTION 1 (short periods up to two or three weeks) and SECTION 2 (maximum duration up to two or three weeks).
Prescriptions for carisoprodol are typically limited to short-term use.
Supported by SECTION 1 (Limitation of Use up to two or three weeks) and SECTION 17 counseling to limit treatment to acute use (up to two or three weeks).
Carisoprodol use is limited to short-term because of dependence risks associated with the drug class.
Partially supported by SECTION 17 noting post-marketing reports of dependence, withdrawal, and abuse with prolonged use; however, the excerpt does not explicitly state the limitation is 'because of dependence risks' (see unsupported).
Unsupported Statements
“Soma 350 mg” typically refers to carisoprodol tablets, 350 mg.
The supplied label excerpts do not contain a statement linking 'SOMA 350 mg' to carisoprodol tablets, though the prompt metadata mentions 350 mg tablets. No verifiable excerpt provided for this specific claim.
Carisoprodol is a muscle relaxant.
Not supported by the provided label excerpts.
Carisoprodol is prescribed for muscle spasm–related pain.
The provided excerpts describe 'discomfort associated with acute, painful musculoskeletal conditions' but do not explicitly use the phrase 'muscle spasm–related pain.'
Carisoprodol is generally used alongside rest and physical therapy measures.
Not supported by the provided label excerpts.
Carisoprodol use is limited to short-term because of sedation risks.
Sedation risks are not mentioned in the provided label excerpts.
Common side effects of carisoprodol include drowsiness.
No adverse reactions/side effects section excerpts were provided.
Common side effects of carisoprodol include dizziness.
No adverse reactions/side effects section excerpts were provided.
Common side effects of carisoprodol include feeling lightheaded.
No adverse reactions/side effects section excerpts were provided.
Carisoprodol can cause impaired alertness.
Not supported by the provided label excerpts.
After taking carisoprodol, driving or operating machinery is often discouraged.
Not supported by the provided label excerpts.
Carisoprodol has known risks of misuse.
SECTION 17 mentions 'abuse' with prolonged use but does not explicitly mention 'misuse' in the provided excerpts.
Carisoprodol has known risks of dependence.
SECTION 17 mentions dependence with prolonged use, but the provided excerpts do not establish 'known risks' wording generally; still, dependence is at least partially supported—this is marked unsupported because the claim is broader than the excerpt.
Many jurisdictions regulate carisoprodol.
Not supported by the provided label excerpts.
Alcohol and other sedating medications can increase drowsiness and impairment with carisoprodol.
No drug interaction or CNS depressant guidance excerpts were provided.
Patients are generally advised to avoid combining carisoprodol with other CNS depressants unless a clinician specifically approves it.
Not supported by the provided label excerpts.
Carisoprodol is different from cyclobenzaprine.
Not supported by the provided label excerpts (comparative claims not present).
Carisoprodol is different from methocarbamol.
Not supported by the provided label excerpts (comparative claims not present).
Carisoprodol is different from tizanidine.
Not supported by the provided label excerpts (comparative claims not present).
Contradictions
Important Omissions
The label excerpt explicitly states the limitation of use is due to lack of adequate effectiveness evidence for more prolonged use (not only dependence/withdrawal/abuse). Any answer that attributes the short-term limitation primarily to sedation or dependence without mentioning the 'lack of established effectiveness for more prolonged use' rationale is missing a material label rationale.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several high-safety-content claims (sedation rationale, driving/operating machinery discouragement, specific side effects, and CNS depressant interaction guidance) are not supported by the provided label excerpts. Short-term duration is supported, which mitigates risk, but unsupported safety counseling could lead to inaccurate patient guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Numerous statements about adverse effects, sedation/driving precautions, and interactions are not supported by the provided prescribing information excerpts.
Suggested Improvement
Restrict claims to what is explicitly present in the provided label text: acute musculoskeletal discomfort indication and short-term limitation up to two or three weeks; dependence/withdrawal/abuse with prolonged use per SECTION 17. Remove or qualify statements about side effects, impaired alertness/driving, sedation rationale, and CNS depressant/Alcohol interaction guidance unless those sections are supplied and cited.